3-氨基-4-溴-2-甲基吡唑 | 105675-85-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 3-氨基-4-溴-2-甲基吡唑
• 中文别名: 3-氨基-4-溴-2-甲基-1H-吡唑；5-氨基-4-溴-1-甲基-1H-吡唑；4-溴-1-甲基-1H-吡唑-5-胺；5-氨基-4-溴-1-甲基吡唑；N-2-甲基-5-氨基-4-溴吡唑
• 英文名称: 4-bromo-1-methyl-1H-pyrazol-5-amine
• 英文别名: 4-bromo-2-methyl-pyrazol-3-amine；4-bromo-2-methyl-2H-pyrazol-3-ylamine；4-bromo-2-methylpyrazol-3-amine
• CAS: 105675-85-2
• 化学式: C₄H₆BrN₃
• 分子量: 176.016
• InChiKey: ODFDZOQJRPDQDF-UHFFFAOYSA-N

物化性质

• 熔点：
  104 °C
• 沸点：
  275℃
• 密度：
  1.91
• 闪点：
  120℃
• 溶解度：
  可溶于乙腈（少许）、DMSO（少许）
• 稳定性/保质期：
  常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封保存于阴凉、干燥的仓库中，并远离氧化剂。

SDS

Name:	4-Bromo-1-methyl-1H-pyrazol-5-amine 97% Material Safety Data Sheet
Synonym:	3-Amino-4-bromo-2-methylparazol
CAS:	105675-85-2

Section 1 - Chemical Product MSDS Name:4-Bromo-1-methyl-1H-pyrazol-5-amine 97% Material Safety Data Sheet
Synonym:3-Amino-4-bromo-2-methylparazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
105675-85-2	4-Bromo-1-methyl-1H-pyrazol-5-amine	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 105675-85-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 103 - 104 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H6BrN3
Molecular Weight: 176.02

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 105675-85-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-1-methyl-1H-pyrazol-5-amine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 105675-85-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 105675-85-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 105675-85-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-4-溴-2-甲基吡唑 在 盐酸 、 sodium nitrite 、 copper(l) chloride 作用下， 以 水 为溶剂， 反应 3.33h， 生成 4-bromo-5-chloro-1-methyl-pyrazole
  参考文献：
  名称：

  Fused Bicyclic Kinase Inhibitors

  摘要：

  公式I的化合物如下所示并在此定义： 其药用可接受盐、合成、中间体、配方以及使用其进行疾病治疗的方法，包括治疗癌症，如至少部分由RON、MET或ALK驱动的肿瘤。本摘要不限制该发明。

  公开号：

  US20110281888A1

文献信息

• MTA-Cooperative PRMT5 Inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US20210078994A1

  公开（公告）日：2021-03-18

  The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制蛋白精氨酸N-甲基转移酶5（PRMT5）活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。
• N-arylsulfilimine compounds and their use as catalysts in the
  申请人：Dow AgroSciences LLC

  公开号：US05973148A1

  公开（公告）日：1999-10-26

  N-arylsulfilimine compounds, such as S,S-dimethyl-N-(2,6-dichlorophenyl)sulfilimine, were prepared and found to catalyze the reaction of aromatic sulfonyl chloride compounds, such as 2-chlorosulfonyl-7-fluoro-5-ethoxy[1,2,4]triazolo[1,5-c]pyrimidine, with aromatic amine compounds, such as 2,6-dichloroaniline, to form N-arylarylsulfonamide compounds, such as N-(2,6-dichlorophenyl)-7-fluoro-5-ethoxy[1,2,4]triazolo[1,5-c]-pyrimidine- 2-sulfonamide. The aryl moiety of the N-arylsulfilimine catalyst and the aryl moiety of the aromatic amine compound were generally chosen to be identical.

  N-芳基磺酰亚胺化合物，例如S，S-二甲基-N-（2，6-二氯苯基）磺酰亚胺，已被制备并发现可催化芳香磺酰氯化合物，例如2-氯磺酰基-7-氟-5-乙氧基[1，2，4]三唑[1，5- c]嘧啶，与芳香胺化合物，例如2，6-二氯苯胺，形成N-芳基芳基磺酰胺化合物，例如N-（2，6-二氯苯基）-7-氟-5-乙氧基[1，2，4]三唑[1，5- c]嘧啶-2-磺酰胺。N-芳基磺酰亚胺催化剂的芳基部分和芳香胺化合物的芳基部分通常被选为相同的。
• [EN] ACLY INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ACLY ET LEURS UTILISATIONS
  申请人：NIMBUS ARTEMIS INC

  公开号：WO2020097408A1

  公开（公告）日：2020-05-14

  The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

  本发明提供了作为ATP柠檬酸裂合酶（ACLY）抑制剂的化合物、其组合物以及使用方法。
• Heterocyclic compounds and their therapeutic use
  申请人：Darwin Discovery, Ltd.

  公开号：US06403791B1

  公开（公告）日：2002-06-11

  A compound of the formula wherein R1 is C1-3 alkyl optionally substituted with one or more fluorines; R2 is C1-6 alkyl, cycloalkyl or NR4R5; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C) NR4R5 is a nitrogen-containing heterocyclic ring; R6 is C1-3 alkyl; and R7 and R8, which are the same or different, each represents C1-3 alkyl, halogen, CF3 or CN; or a pharmaceutically-acceptable salt thereof.

  其中R1是C1-3烷基，可选地被一个或多个氟原子取代；R2是C1-6烷基、环烷基或NR4R5；R3是部分公式（A）、（B）或（C）的吡唑、咪唑或异恶唑基团；NR4R5是含氮杂环；R6是C1-3烷基；R7和R8相同或不同，每个代表C1-3烷基、卤素、CF3或CN；或其药物可接受的盐。
• [EN] MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES À GROUPES HÉTÉROCYCLIQUES P2' SERVANT D'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015116886A1

  公开（公告）日：2015-08-06

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。